Cocrystal pharma announces first-patient-in for phase 2a human challenge study evaluating oral cc-42344 in pandemic and seasonal influenza a

Bothell, wash., dec. 06, 2023 (globe newswire) -- cocrystal pharma, inc. (nasdaq: cocp) (“cocrystal” or the “company”) announces the achievement of first-patient-in for the phase 2a human challenge clinical trial with cc-42344, an investigational new oral antiviral inhibitor for the treatment of pandemic and seasonal influenza a. this randomized, double-blind, placebo-controlled study will evaluate the safety, tolerability, viral and clinical measurements of influenza a infection in subjects dosed with oral cc-42344 treatment.
COCP Ratings Summary
COCP Quant Ranking